Evidence map›Paper›PMID 38140118›Full record

ArticlePharmaceutics2023

Pre-Clinical Investigations of the Pharmacodynamics of Immunogenic Smart Radiotherapy Biomaterials (iSRB).

Michele Moreau, Shahinur Acter, Lindokuhle M Ngema, Noella Bih, Gnagna Sy, Lensa S Keno, Kwok Fan Chow, Erno Sajo, Oscar Nebangwa, Jacques Walker and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Michele MoreauDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-6881-6300
Shahinur ActerDepartment of Radiation Oncology & Molecular Radiation Sciences, Johns' Hopkins Hospital, Baltimore, MD 21287, USA.ORCID 0000-0001-7908-3870
Lindokuhle M NgemaDepartment of Radiation Oncology & Molecular Radiation Sciences, Johns' Hopkins Hospital, Baltimore, MD 21287, USA.ORCID 0000-0003-4547-4392
Noella BihDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Gnagna SyDepartment of Radiation Oncology & Molecular Radiation Sciences, Johns' Hopkins Hospital, Baltimore, MD 21287, USA.ORCID 0000-0001-7610-8788
Lensa S KenoDepartment of Health Administration and Human Resources, The University of Scranton, Scranton, PA 18510, USA.
Kwok Fan ChowDepartment of Chemistry and Department of Physics (Medical Physics), University of Massachusetts Lowell, Lowell, MA 01854, USA.
Erno SajoDepartment of Chemistry and Department of Physics (Medical Physics), University of Massachusetts Lowell, Lowell, MA 01854, USA.ORCID 0000-0001-6802-0014
Oscar NebangwaNanocan Therapeutics Corporation, Princeton, NJ 08540, USA.
Jacques WalkerNanocan Therapeutics Corporation, Princeton, NJ 08540, USA.
Philmo OhNanocan Therapeutics Corporation, Princeton, NJ 08540, USA.
Eric BroylesNanocan Therapeutics Corporation, Princeton, NJ 08540, USA.
Wilfred NgwaDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Sayeda Yasmin-KarimDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Brigham and Women's Hospital · USJohns Hopkins Hospital · USUniversity of Massachusetts Lowell · USUniversity of Scranton · USUniversity of the Witwatersrand · ZA

Funding

Biomaterial Drones for Image-Guided Drug Delivery during radiotherapyR01CA239042 · NCI · JOHNS HOPKINS UNIVERSITY · PI NGWA, WILFRED · 2019 to 2023
$3.2M
NCI NIH HHS R01 CA239042NIH HHS R01CA239042
6 · The paper itself

Abstract

The use of an immunogenic smart radiotherapy biomaterial (iSRB) for the delivery of anti-CD40 is effective in treating different cancers in animal models. This study further characterizes the use of iSRBs to evaluate any associated toxicity in healthy C57BL6 mice. iSRBs were fabricated using a poly-lactic-co-glycolic-acid (PLGA) polymer mixed with titanium dioxide (TiO

Indexed as

anti-CD40 monoclonal antibodyclinical chemistryhematologyhistopathologysmart radiotherapy biomaterialstoxicity

Identifiers

PMID38140118
PMCPMC10747552
OpenAlexW4389793948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.